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Abstract 
The platinum(IV) prodrug trans,trans,trans-[Pt(N3)2(OH)2(py)2] (1) is stable and non-toxic in the dark, 
but potently cytotoxic to cancer cells when irradiated by visible light, including cisplatin-resistant cells. 
On irradiation with visible light, it generates reactive Pt(II) species which can attack DNA, and produces 
reactive oxygen species (ROS) and reactive nitrogen species (RNS) which exert unusual effects on 
biochemical pathways. We now show that its novel mechanism of action includes induction of 
immunogenic cell death (ICD). Treatment of cancer cells with 1 followed by photoirradiation with 
visible light induces calreticulin (CRT) expression at the surface of dying cancer cells. This is 
accompanied by release of high mobility group protein-1B (HMGB1) and the secretion of ATP. 
Autophagy appears to play a key role in this chemotherapeutically-stimulated ICD. The observed 
uneven distribution of ecto-CRT promotes phagocytosis, confirmed by the observation of engulfment 
of photoirradiated CT26 colorectal cancer cells treated with 1 by J774.A1 macrophages. The 
photoactivatable prodrug 1 has a unique mechanism of action which distinguishes it from other platinum 




Platinum complexes represent a widely used class of anticancer drugs.1 Some of these agents, 
e.g., cisplatin and its derivatives (carboplatin and oxaliplatin), belong to an important group of 
clinical cytostatics which are very successful both medicinally and commercially. Their clinical 
use is, however, limited due to undesirable side effects and a relatively narrow spectrum of 
sensitive tumors. These drawbacks provide an impetus for the search and design of new, more 
effective antitumor platinum complexes, which might overcome the limitations connected with 
the clinical use of conventional platinum cytostatics. 
For cisplatin and carboplatin, it is generally accepted that nuclear DNA is the major 
pharmacological target of their anti- tumor action.1,2 In other words, their antitumor effects are 
a consequence of their capability of damaging DNA in a unique way and the subsequent 
processing of this damage by cellular components.3–5 A very large number of new antitumor 
platinum complexes have been tested, including agents whose mechanism of action (MoA) has 
been associated with an ability to damage DNA similar to cisplatin, but also some have a 
different MoA or a combination of various MoAs. The development of photoactivatable 
platinum(IV) complexes is a new strategy for design of antitumor platinum complexes which 
would act by an MoA different from that of cisplatin and its direct derivatives.6,7 A promising 
complex in this class of photoactivatable platinum antitumor prodrugs is trans,trans, trans-
[Pt(N3)2(OH)2(py)2] (1) (Fig. 1).
8–10 
 
Figure 1. The structures of cisplatin, oxaliplatin, and complex 1. 
This PtIV diazido complex is unreactive in the dark, but potently cytotoxic when 
photoactivated by UVA and visible light even in cisplatin-resistant tumor cell lines, with a high 
phototoxicity index. With regard to its MoA, the octahedral PtIV prodrug 1 is reduced upon 
photoactivation to square planar PtII species, which bind strongly to nuclear DNA and are toxic 
to tumor cells.11,12 Notably, DNA damage by photoactivated 1 produces several downstream 
cellular effects different from those triggered in cancer cells by cisplatin-damaged DNA. 
Moreover, photo-reduction of 1 results in the release not only of PtII species, but also of other 
photo-products including azidyl and hydroxyl radicals, nitrenes, and singlet oxygen.8,9 These 
photoreduction products can modulate biochemical pathways in tumor cells which are not 
involved in the MoA of cisplatin and its direct derivatives, thus pointing to a novel MoA for 
1.9 
One possibility of how the photoreduction products of 1 might act by an MoA different 
from that involving DNA damage (and typical for cisplatin and its direct derivatives) is that 
irradiated 1 could induce an immunogenic form of cell death (ICD). This suggestion is 
corroborated by convincing evidence demonstrating that some conventional antitumor 
metallodrugs (including oxaliplatin and its analogs13–17) can also induce ICD that 
synergistically enhances their anticancer efficiency, confirming the immunomodulating 
capability of chemotherapy. It has also been shown15,18–20 that ICD-associated immunogenicity 
can be evoked through reactive oxygen species (ROS). Thus, it was reasonable to assume that 
the photoactivated 1, which generates ROS and RNS,8,9 could induce, besides apoptosis, also 
ICD. Therefore, we investigated whether photoactivated 1 can induce ICD in vitro, which could 
synergistically enhance its anticancer efficiency, thus corroborating the immunomodulating 
capability of chemotherapy based on this photoactivatable PtIV prodrug. 
 
Results and discussion 
ICD is characterized by a series of biochemical hallmarks including: (i) translocation of ER-
resident calreticulin (endo-CRT) to the cell surface (ecto-CRT) during early apoptosis; (ii) 
active secretion of ATP; (iii) extracellular secretion of nuclear high-mobility group box 1 
protein (HMGB1) at late-stage apoptosis.21 Additionally, a critical step for ICD is the 
engulfment of dying cancer cells by dendritic cells,22 so the ICD inducers should also increase 
tumor cell phagocytosis.16 Therefore, to determine whether photoactivated 1 can be identified 
as an immuno-chemotherapeutic agent, we examined its capability of displaying the 
aforementioned characteristic hallmarks of ICD. 
Irradiated 1 induces calreticulin exposure 
Under the physiological (non-stress) conditions, CRT is usually located in the lumen of the 
endoplasmic reticulum (ER). CRT is translocated to the cell membrane during ICD stimulation 
(termed ecto-CRT). Thus, immunogenic chemotherapy induces CRT exposure at the cell 
surface of dying cells, which acts as the dominant pro-phagocytic signal promoting the 
engulfment of cancer cells.22,23 
Human A2780 ovarian cancer cells were treated with increasing concentrations of 1 in 
the dark or under irradiation conditions [420 nm (blue light), 77 W m−2, 30 min] for 2 h. The 
cells were subsequently washed and incubated for another 22 h in drug-free medium (for 
details, see the Experimental section in the ESI†) to stimulate an adequate cellular response. In 
these experiments, the anthracycline antimetabolite doxorubicin22 and oxaliplatin13 were used 
for comparative purposes as positive controls, whereas cisplatin24 served as the negative 
control. The samples were fixed by 4% formaldehyde, stained with antiCRT-alexa fluor 488 
conjugate, and counterstained with propidium iodide. These samples were further analyzed 
using flow-cytometry. Propidium iodide-negative cells were gated out to eliminate possible 
false-positive results due to the non-specific accumulation of anti-CRT antibody through the 
compromised cell membranes of dying cells (Fig. 2). Data were analyzed in terms of the overall 
mean fluorescence (mean fluorescence intensity; MFI) (Fig. 2B) and percent of the propidium 
iodide negative/CRT positive population (Fig. 2C). The histograms for irradiated samples are 
shown in Fig. 2A, whereas histograms obtained for samples kept in the dark are shown in ESI 
Fig. S1.† 
 
Figure 2. Analysis of ecto-CRT exposure after the treatment of A2780 cells with the 
investigated compounds. A2780 cells were untreated or treated with the indicated 
concentration of the tested compound for 2 h in the dark, or under irradiation conditions [90 
min pre-incubation followed by irradiation with blue light (420 nm, 77 W m−2, 30 min)]; the 
samples were subsequently incubated for 22 h in the drug-free medium, and then analyzed by 
flow cytometry. A. Representative histograms from five independent experiments. B. Samples 
analyzed for overall mean fluorescence. C. Samples analyzed as the CRT-positive/PI-negative 
population. Stars (*) and hashes (#) at the top of the bars in both Fig. 2B and C indicate 
statistically significant difference from the untreated control (p ≤ 0.01) and statistically 
significant difference between irradiated and nonirradiated samples (p ≤ 0.01), respectively. 
Three independent experiments were done in quadruplicate for each sample set and the data 
in Fig. 2B and C show the mean ± SD. 
 
The amount of immuno-detectable ecto-CRT observed on the surface of non-treated 
A2780 cells in the dark and under irradiation conditions was very small. Unsurprisingly, when 
cisplatin (20 μM), incapable of inducing ICD, was added to A2780 cells both in the dark or 
under irradiation conditions, the induction of ecto-CRT exposure remained low, comparable 
with that observed for the untreated cells. In contrast, wellknown ICD inducers doxorubicin 
(20 μM) and oxaliplatin (100 μM) caused a relatively extensive induction of ecto-CRT 
exposure both in the dark and under irradiation conditions (Fig. 2B and C). Importantly, 1 (1 
or 5 μM) induced ecto-CRT exposure extensively under irradiation conditions, but it was 
ineffective in the dark. 
As another means of exploring the efficiency of 1 to induce ecto-CRT exposure, we 
investigated ecto-CRT exposure by confocal microscopy (Fig. 3). A2780 cells were treated 
with 1 and kept in the dark or under the irradiation conditions (vide supra). Then, the cells were 
fixed with 4% formaldehyde under non-permeabilizing conditions and stained with the anti-
CRTalexa fluor 488 conjugate. Samples were visualized by confocal microscopy. It is shown 
in Fig. 3 that the fluorescence signal yielded by the cells stained by anti-CRT-alexa fluor 488 
antibodies is localized on the cell membrane of the cells treated with 1, but only when the cells 
treated with 1 were irradiated. Qualitatively identical results were obtained when the cells were 
treated with doxorubicin and oxaliplatin (ESI Fig. S2†). In contrast, the untreated cells or cells 
treated with the 1 in the dark or with cisplatin yielded no fluorescence signal indicating lack of 
calreticulin exposure. 
 
Figure 3. Immunofluorescence analysis of ecto-CRT exposure by confocal microscopy. A2780 
cells were untreated or treated with 1 (5 μM) for 2 h in the dark (panels 1 and 2, respectively) 
or under irradiation conditions [90 min pre-incubation followed by irradiation with blue light 
(420 nm, 77 W m−2, 30 min)] (panel 3); the samples were subsequently incubated for 22 h in 
the drug-free medium. Channels: A. Fluorescence signal from CRT-Alexa fluor 488 conjugate. 
B. Bright field. C. Merge of the fluorescence and bright field channels. Scale bars represent 
10 μm. 
The results of analysis by confocal microscopy of A2780 cells treated with 
photoactivated 1 showed an uneven distribution of ecto-CRT on the surface of the cells Fig. 
3C. This phenomenon was also observed for other ICD inducers and was proposed to promote 
phagocytosis.25,26 Collectively, the results of the confocal microscopic experiments are 
consistent with the conclusions drawn13,26,27 on the basis of flow cytometric analysis (Fig. 2) 
demonstrating that photoactivated 1 promotes surface exposure of calreticulin (ecto-CRT) 
which has emerged as a key mediator of the immunogenicity of dying tumor cells.22 
 
Release of the high mobility group box 1 protein (HMGB1) and ATP to the extracellular 
environment. 
In response to immunogenic chemotherapeutics, dying cells release HMGB1 protein, and 
secrete ATP into the extracellular environment after permeabilization of nuclear and 
cytoplasmic membranes, stimulating an immunogenic response. Moreover, neutralization or 
depletion of HMGB1 leads to the loss of the immunogenicity of cell death.28 Thus, the release 
of the nuclear HMGB1 and ATP secretion to extracellular milieu determines, together with the 
induction of ecto-CRT exposure, the immunogenicity of dying tumor cells.29–31 It is also 
important to mention that ecto-CRT exposure, HMGB1 release, and ATP secretion are all 
indispensable for ICD, i.e., that the absence of even one of these ICD hallmarks abolishes the 
efficacy of immunochemotherapy.15,31 
To verify whether HMGB1 release and ATP secretion play a role in the mechanism of 
action of photoactivated 1, we analyzed stimulation of HMGB1 release and ATP secretion in 
the cell culture supernatants of A2780 cells incubated in the dark and under irradiation 
conditions with 1, and for comparative purposes also doxorubicin, oxaliplatin, and cisplatin. 
HMGB1 release was detected by the enzyme-linked immunosorbent assay (ELISA), and the 
extracellular ATP from cell supernatants was analyzed with the ATP bioluminescence assay 
kit CLSII (Roche). 
Photoactivated (irradiated by visible light) 1 along with doxorubicin and oxaliplatin 
(both in the dark) induced the marked release of HMGB1 and ATP from the nuclei of ovarian 
A2780 cancer cells in a concentration-dependent manner (Fig. 4 and 5, respectively). In 
contrast, no or very low extracellular release of nuclear HMGB1 and ATP was detected if the 
A2780 cells were untreated or treated with 1 and cisplatin in the dark. Altogether, these results 
corroborate the importance of HMGB1 and ATP release into the extracellular environment for 
the immune response against tumor cells dying in response to photoactivated 1. Notably, when 
doxorubicin or oxaliplatin was added to A2780 cells under irradiation conditions, the release 
of HMGB1 and ATP secretion decreased considerably as compared to that found for the 
treatment with doxorubicin or oxaliplatin in the dark (Fig. 4). Similarly, the induction of ecto-
CRT exposure considerably decreased after doxorubicin or oxaliplatin was added to A2780 
cells under irradiation conditions as compared to that found for the treatment with doxorubicin 
or oxaliplatin in the dark (Fig. 2). It is, therefore, possible to expect that the combination of 
doxorubicin or oxaliplatin chemotherapy with photodynamic therapy by other agents might 
decrease the chemotherapeutic effects of these two drugs or alter their ability to induce ICD. 
 
Figure 4. Extracellular release of (A) HMGB1, and (B) ATP. A. A2780 cells were untreated or 
treated with the indicated concentrations of the tested compound for 2 h in the dark or under 
irradiation conditions [90 min pre-incubation followed by irradiation with blue light (420 nm, 
77 W m−2, 30 min). The samples were subsequently incubated for 22 h in the drug-free 
medium, and then analyzed by the ELISA assay. The results are expressed as the absorbance 
at 420 nm corresponding to the product yielded by the ELISA enzyme, which is proportional 
to the amount of HMGB1 protein released from the cells. B. A2780 cells were treated with the 
indicated concentrations of the tested compounds as described for panel A. The samples were 
analyzed by the ATP bioluminescence assay. Data are expressed as the mean luminescence 
intensity [RLU] or normalized to untreated non-irradiated control samples expressed in 
percentages. Stars (*) and hashes (#) at the top of the bars in both Fig. 4A and B indicate 
statistically significant difference from the untreated control (p ≤ 0.01) and statistically 
significant difference between irradiated and non-irradiated samples (p ≤ 0.01), respectively. 
Three independent experiments were done in quadruplicate for each sample set and the data 
in Fig. 4a and B show the mean ± SD. 
 
Involvement of autophagy in ICD-associated ATP secretion 
Autophagy plays a crucial role in ATP secretion during chemotherapeutically stimulated 
ICD.32 This conclusion is also corroborated by the observation that autophagy-deficient cells 
are unable to trigger tumor-targeting immune responses.33 Additionally, the autophagy-
deficient tumors growing in immunocompetent hosts are generally less sensitive to anti- 
cancer agents that actively promote a therapeutically relevant immune response like 
doxorubicin and oxaliplatin.34,35 Moreover, functional autophagy machinery is required for 
survival of the cells involved in adaptive anticancer immunity, like cytotoxic T-lymphocytes.36 
Activating autophagy in treated tumors may boost the overall efficacy of anticancer therapy, 
mainly in terms of ICD.37 
Since autophagy can play an essential role in the immunogenic release of ATP from 
dying cells, we examined the relationship between extracellular ATP release driven by the 
autophagy machinery and cell death by means of multi-parameter flow cytometry. We analyzed 
three main modes of cell death (apoptosis, necrosis, and autophagy) initiated after the treatment 
of ovarian cancer cells A2780 with 1. All three main modes of cell death were analyzed directly 
in one experiment, to compare the direct contribution of each mode on the overall death of the 
treated cells. 
A2780 cells were treated with 1 in the dark and under irradiation conditions, and 
apoptotic, necrotic, and autophagic mechanisms of cell death were measured by flow 
cytometry. The results were compared with the effects of the established specific cell-death 
inducers, namely staurosporine, a known inhibitor of protein kinases, for specific induction of 
apoptosis, which was detected by annexin-V, EtOH, a known stimulator of non-specific 
necrosis, which was detected by propidium iodide, a combination of rapamycin and 
chloroquine, known stimulators of autophagy, which was detected with a Cyto-ID probe 
(rapamycin stimulates the accumulation of autophagic vacuoles and the autophagic flux, 
whereas chloroquine increases lysosomal pH, thereby inhibiting lysosomal activity during 
autophagosome-lysosome fusion38). As a result, this combinatorial treatment provides more 
autophagy-positive cells than single-agent treatment. 
Cells treated with 1 in the dark displayed only very small changes over the untreated 
control in the distribution among the investigated types of cell death (Fig. 5). In contrast, 
photoactivated (irradiated by visible light) 1 induced cell death mainly via autophagic and, to 
a lesser extent, via apoptotic pathways (Fig. 5). Thus, these results support the view, and are 
consistent with, the hypothesis that autophagy is essential for the immunogenic release of ATP 
from dying cells when A2780 cells are treated with photoactivated 1. 
 
Figure 5. Analysis of the mode of cell death. A2780 cells were treated with 1 or 5 μM of 1 for 
90 min; then, the samples were further incubated for an additional 30 min in the dark or under 
irradiation conditions (blue light 420 nm, 77 W m−2). Fluorescence signals yielded by the 
specific probes for apoptosis (annexin-V), necrosis (propidium iodide), and autophagy (Cyto-
ID) were analyzed by flow cytometry. The cells were also treated with staurosporine (positive 
control for apoptosis) (1 μM, 3 h), EtOH (positive control for necrosis) [10% (v/v), 90 min] 
and rapamycin with chloroquine (positive control for autophagy) (0.5 and 50 μM, 18 h). The 
results are expressed as the mean number of the cells (%) positive for the specific cell death 
probe. Three independent experiments were done in quadruplicate for each sample set. 
 
In vitro phagocytosis assay 
Besides the externalization of ecto-CRT, the release of HMGB1 and secretion of ATP, also 
efficient phagocytic removal by professional phagocytes belong to the most important 
biochemical hallmarks of ICD.39 Additionally, phagocytosis was shown to be mediated by cell 
surface exposure of ecto-CRT. On the other hand, it has been also demonstrated that 
translocation of CRT to the cell surface is necessary, but not sufficient for the induction of 
phagocytosis. The clinically used platinum(II) antitumor drug oxaliplatin has been presented 
as a compound capable of effective externalization of ecto-CRT and induction of ICD,13 but 
also being unable to promote phagocytosis.26 Therefore, we evaluated in an in vitro 
phagocytosis assay to determine whether photoactivated 1 can increase tumor cell phagocytosis 
over non-treated controls or 1 in the dark. 
To do this, murine CT26 carcinoma cells (colon fibroblasts), used as a model for studies 
on the immune response, were untreated or treated with 1 in the dark or under irradiation 
conditions as described in the Experimental section and coincubated with murine J774.A1 
macrophages. CT26 cells and J774.A1 macrophages were pre-stained with CellTrackerTM 
green CMFDA and CellTrackerTM red CMTPX, respectively, and analyzed by flow cytometry 
(Fig. 6A–C and S3†) and confocal microscopy (Fig. 6D and E). Representative flow cytometry 
density plots showing phagocytosis (top right quadrant) with 1 in the dark and irradiated 1 
(both at 10 μM concentration) are shown in Fig. 6B and C, respectively. 
 
Figure 6. In vitro phagocytosis assay. Green-stained murine CT26 carcinoma cells were 
treated with the investigated compounds at the indicated concentrations for 24 h and 
subsequently co-incubated with red-stained J774.A1 murine macrophages for 3 h. A. Analysis 
of phagocytosis in CT26 cells by flow cytometry. The percentage of phagocytosis was 
calculated from the number of double-stained macrophages compared to the total number of 
macrophages. B and C. Representative flow cytometry density plots showing the phagocytosis 
after the treatment with 1 (10 μM) in the dark (B) or upon irradiation (C). D and E. Confocal 
microscopy of J774.A1 macrophages (red) engulfing CT26 cells (green) is evident by mixing 
of the dyes. The symbols I, II, and III in the panels D and E indicate the red-stained J774.A1 
macrophages, the green-stained CT26 fibroblasts, and the overlay of the red, green and bright 
field channels, respectively. Scale bars in panels D and E represent 30 or 60 μm, respectively. 
Photoactivation of 1 markedly increased tumor-cell phagocytosis compared with 1 in the dark 
or non-treated controls (35.1 ± 5.6% vs. 2.8 ± 0.4% or 2.4 ± 0.2%, respectively, p < 0.001) (see 
also Fig. 6A). Other representative flow cytometry density plots showing phagocytosis with 
doxorubicin, cisplatin, and oxaliplatin are shown in the ESI Fig. S3.† Except for doxorubicin 
(20 μM, a well-known inducer of ICD and phagocytosis40), the other investigated compounds, 
cisplatin (20 μM, incapable of inducing ICD16) and oxaliplatin (100 μM, classical ICD 
inducer13,41) promoted phagocytosis only negligibly irrespective of dark or irradiated 
conditions (Fig. 6A). Collectively, our results indicate that the photoactivation of 1 markedly 
promotes tumor cell phagocytosis and also confirm that although oxaliplatin induces ICD and 
key pro-phagocytic signal ecto-CRT exposure,42 it does not promote tumor cell 
phagocytosis.26 
Phagocytosis induced by photoactivated 1 was also verified by confocal microscopy 
(Fig. 6D), which showed the contact of red-colored murine J774.A1 macrophages with green-
colored murine CT26 carcinoma cells. Moreover, analysis by confocal microscopy also 
revealed engulfment of CT26 cells by J774. A1 macrophages, demonstrated in Fig. 6D-III by 
mixing of the fluorescent red and green dyes in the area of the engulfment. The control 
experiments performed with cells treated with 1 in the dark showed that both co-incubated C26 
and J774.A1 cells were well separated without mixing of the fluorescent red and green dyes 
(Fig. 6E). Thus, the results of the confocal microscopic analysis are entirely consistent with the 
analysis by flow cytometry, confirming the ICD-stimulatory effect of 1 when photoactivated 
with visible light. 
In summary, this report demonstrates a new mechanism of antitumor action of 
trans,trans,trans-[Pt(N3)2(OH)2(py)2] (1), a photoactivatable Pt
IV-based chemotherapeutic 
agent, which besides DNA damage12 also involves synergistic action through induction of an 
immunogenic form of cell death (ICD). This prodrug, when photoactivated by visible light, 
was found to display the characteristic hallmarks of ICD inducers, namely calreticulin 
exposure, HMGB1 and ATP release in ovarian carcinoma cells, and promotion of tumor cell 
phagocytosis in model murine (colon fibroblasts) carcinoma cells. Additionally, autophagy was 
found to be essential for the immunogenic release of ATP from dying tumor cells which had 
been treated with the PtIV prodrug and photoirradiated. 
It seems likely that the molecular mechanism of the ICD induced by photoactivated 1 
involves oxidative attack on proteins (e.g. on Met and Trp residues) by the ROS and RNS, and 
perhaps also by the PtII species, it generates.7,43 In particular photoactivated 1 induces oxidation 
of Met, Trp and the Cys residues in the catalytic center of the enzyme thioredoxin reductase 
(TrxR), which protects cells against ROS, resulting in inhibition of TrxR activity and further 
ROS damage.44 Therefore it is possible that 1 acts as a type II ICD inducer, with ROS directly 
triggering ER stress, resulting in exposure of calreticulin.41 That the generated ROS could 
damage the ER was confirmed by confocal microscopy (Fig. S4†). The results of this 
experiment show that after the cells treated with 1 were irradiated, the ROS were produced in 
the whole cytoplasm, including the ER. This type of ICD induction is rarer than type I (indirect 
activation of ER stress) which has previously been observed for oxaliplatin, but has been 
reported for some other agents including a cyclometallated PtII complex which targets the ER.26 
Clinical application of photochemotherapy is currently based on photosensitizers for 
photodynamic therapy, which typically need oxygen to exert their anticancer action. As many 
malignant and most aggressive tumors are of oxygen-deficient nature,45 the requirement for 
oxygen is a major drawback of these phototherapeutic agents. In contrast, the investigated 
platinum(IV) prodrug 1 does not require the presence of oxygen for its anticancer effects, as 
these stem from chemical photodecomposition of 1 to release cytotoxic species.9 Accordingly, 
1 presents a potential key advantage over PDT photosensitizers. Thus, this photocytotoxic PtIV 
complex was identified as the first platinum immuno-chemotherapeutic agent suitable for 
photochemotherapy also in the hypoxic milieu of tumors. 
It might be argued that 1 is photoactivated by irradiation with light of a relatively short 
wavelength (420 nm). This fact might be a limitation for the clinical application of this 
diazidoplatinum(IV) complex since the light of such high energetic wavelengths can poorly 
penetrate some solid tumors. However, the current level of laser and fiber-optic methodologies 
allows also irradiating internal organs with light of defined wavelength, including blue light.6 
On the other hand, the capability of longer-wavelength light, which penetrates deeply into 
tumor tissue might, in some cases also be a drawback of photodynamic therapy. The choice of 
the optimal wavelength range also depends on the depth of tumor invasion; unnecessary deeper 
tissue penetration may also impair the potency of photodynamic therapy and damage 





Trans,trans,trans-[Pt(N3)2(OH)2(py)2] (1) was synthesized and characterized by the method 
described previously.11 Oxaliplatin, doxorubicin, staurosporine, rapamycin, chloroquine were 
from Merck (Germany). Ovarian carcinoma A2780 cells were kindly supplied by Professor B. 
Keppler from the University of Vienna (Austria). Murine (colon fibroblasts) CT26 carcinoma 
cells and murine J774.A1 macrophages were from ECACC (UK). 3-(4,5-Dimethyl-2- 
thiazolyl)-2,5-diphenyl-2Htetrazolium bromide (MTT) was from Calbiochem (Darmstadt, 
Germany). 
Cell treatment schedule and irradiation 
The cells were incubated with the relevant agent for a total of 2 h in the dark or under irradiation 
conditions [420 nm (blue light), 77 W m−2, for 30 min after 90 min incubation]. The cells were 
subsequently washed and incubated for another 22 h in the drug-free medium. A Luzchem 
photoreactor [LZC-ICH2 from Luzchem (Canada)] with temperature controller and with blue 
lamps [77 W m−2 (28 J cm−2); λmax = 420 nm] was used for irradiation. The medium in which 
the irradiation was performed consisted of Hank’s Balanced Salt Solution HBSS without 
antibiotics or any additives. The temperature in the light chamber during irradiation was 37 °C. 
After the irradiation, cells were washed with HBSS, and samples were loaded with full culture 
medium containing antibiotics and FBS. 
Antiproliferative activity 
The antiproliferative activity of the investigated compounds was evaluated by using a system 
based on the tetrazolium compound MTT. The A2780 cells were seeded in 96-well tissue 
culture plates at a density of 1 × 104 cells per well in 100 μL of the medium. After overnight 
incubation (16 h) at 37 °C in a 5% CO2 humidified atmosphere, the medium from the wells was 
removed, and cells were treated according to the procedure described in the preceding 
paragraph. After an additional 70 h incubation, 20 μL of MTT solution (1.25 mg mL−1 in PBS) 
was added to each well, and the plates were incubated for 4 h. At the end of the incubation 
period, the medium was removed and the formazan product was dissolved in 100 μL of DMSO. 
The cell viability was evaluated by measurement of the absorbance at 570 nm (reference 620 
nm), using an Absorbance Reader (SPARK, Tecan). All experiments were made in triplicate. 
The readings were converted to the percentage of control (% cell survival). Antiproliferative 
effects were expressed as IC50 values calculated from curves constructed by plotting cell 
survival (%) versus drug concentration (μM) (IC50 = concentration of the agent inhibiting cell 
growth by 50%). Concentrations of Pt platinum compounds present in medium during the 
treatment were verified by FAAS. 
Exposure of calreticulin 
Two independent experimental methods were used to identify CRT exposure. The samples 
were quantitatively analyzed using flow cytometry, whereas the qualitative analysis was 
performed with the aid of confocal microscopy. 
Detection of CRT exposure by flow cytometry. A2780 cells were seeded on the 6-well plate 
at the density of 2 × 105 cells per well and incubated overnight. Then the cells were treated with 
1 (1 and 5 μM), doxorubicin (20 μM), oxaliplatin (100 μM) or cisplatin (20 μM), and then 
further incubated as described above. Subsequently, the cells were fixed with 4% formaldehyde 
and stained with antiCRT-alexa fluor 488 conjugate (Abcam). Before the analysis on a flow 
cytometer (BD FACSVerse), the cells were co-stained with propidium iodide. Single cells (3 
× 104) were analyzed and plotted on the histogram with a bi-exponential scale. For population 
analysis, acquired events were plotted on 2D density plots, and the CRTpositive population 
was identified in CRT+/PI-quadrant; the number of the cells was expressed in percentages from 
the single gated cells. Data were analyzed using FCS Express 6 (DeNovo software; Glendale, 
CA). 
Detection of CRT exposure by confocal microscopy. A2780 cells were seeded on 50 mm 
glass-bottom culture dishes (Mattek, Ashland, USA) at a density of 2 × 105 cells per dish, and 
incubated overnight. Then the cells were treated with 1 (1 and 5 μM), doxorubicin (20 μM), 
oxaliplatin (100 μM) or cisplatin (20 μM) and the treatment continued as described above. 
Subsequently, the cells were fixed with 4% formaldehyde and stained with antiCRT-alexa fluor 
488 conjugate (Abcam). Samples were visualized on a confocal microscope Leica TCS SP8 
SMD (Leica microsystems GmbH, Wetzlar, Germany). 
Release of the high mobility group box 1 protein (HMGB1) to the extracellular space 
The release of the HMGB1 protein was assayed using the ELISA kit from IBL International 
(Tecan). A2780 cells were seeded on 96-well plates (TPP) at a density of 10 000 cells per well 
and incubated for 48 h. Then the cells were treated with the increasing concentrations of 1 (1, 
5, 10 μM), doxorubicin (10, 20 μM), oxaliplatin (50, 100 μM), or cisplatin (10, 20 μM), and 
the treatment continued as described above. After the treatment period, supernatants from 
centrifuged samples were transferred into the 96-well plate provided by the manufacturer with 
the wells containing the immobilized HMGB1 protein. The experimental protocol for the 
ELISA assay described in the manufacturer instructions was used. At the end of the assay, the 
colorimetric product was analyzed on a SPARK (Tecan) reader. The absorbance measured at 
420 nm was proportional to the amount of HMGB1 protein released from the cells. 
Extracellular ATP analysis 
Extracellular ATP released from A2780 cells was detected using an ATP bioluminescence 
assay kit CLSII (Roche). A2780 cells were seeded on the 96-well black plate (Corning) at the 
density of 10 000 cells per well and incubated overnight. Then, the cells were treated with 
increasing concentrations of 1 (0.5, 1, 5, 10 μM), doxorubicin (5, 10, 20 μM) or oxaliplatin (50, 
100, 200 μM) for 90 min and incubated at 37 °C, 5% CO2 in the dark. Subsequently, the cells 
were irradiated with blue light or incubated in the dark for another 30 min. Then, the samples 
were washed with HBSS and incubated for 22 h in drug-free medium. The cells were 
centrifuged (200 g, 5 min), and supernatants were analyzed by using an ATP bioluminescence 
assay kit CLSII according to the manufacturer’s instructions. Luminescence was measured on 
a SPARK reader (Tecan). The results are expressed as the mean luminescence intensity, or 
normalized to the untreated, non-irradiated control. 
Determination of the mode of cell death 
Apoptotic, necrotic, and autophagic mechanisms of cell death were investigated by the flow 
cytometry. A2780 cells were seeded on the 6-well plate at the density of 2 × 105 cells per well 
and incubated overnight. The cells were further treated as described in the section “Treatment 
schedule and irradiation of the samples” with 1 at the concentration of 0, 5, or 10 µM for 1 h 
in Earle’s Balanced Salt Solution (EBSS). Staurosporine, ethanol, and chloroquine with 
rapamycin were used as the positive controls for apoptosis, necrosis, and autophagy, 
respectively. The cells were treated with 1 µM staurosporine for 3 h, while ethanol was added 
at 10% v/v for 90 min. Chloroquine was added at the final concentration of 50 µM together 
with 500 nM of rapamycin for 18 h in the culture media at 37 °C, 5% CO2. The cells were 
harvested with CellStriper (Corning) at the end of the incubation period, pelleted, subsequently 
stained with CYTO-ID® autophagy detection probe, and incubated for another 30 min in the 
culture medium without phenol red in a humidified CO2 incubator. Then, the cells were 
centrifuged for 3 min at 300 g and stained with propidium iodide and annexin-V for 15 min at 
25 °C. Samples were subsequently analyzed on a flow cytometer (BD FACSVerse). Data were 
analyzed using FCS Express 6 (DeNovo software; Glendale, CA). 
In vitro phagocytosis assay 
J774.A1 murine macrophages were seeded in a 75 cm2 flasks at the density of 2 × 106 cells and 
incubated for 48 h. Murine CT26 cells were seeded in 6-well plate at the density of 1.5 × 105 
cells per well and incubated overnight. The cells were further treated as described in the section 
“Treatment schedule and irradiation of the samples”. Then, both cell lines were stained by cell 
trackers. J774.A1 macrophages were stained with CellTracker™ red CMTPX, and CT26 
fibroblasts were stained with CellTracker™ green CMFDA, both from Invitrogen. The cells 
were co-incubated at the 1 : 5 macrophage : fibroblast ratio for 3 h, harvested, and fixed for 10 
min with 4% formaldehyde. Phagocytosis was evaluated using flow cytometry (BD 
FACSVerse), and data were analyzed with the aid of FCS Express 6 (DeNovo software; 
Glendale, CA). Samples were also analyzed by confocal microscope using a Leica TCS SP8 
SMD (Leica microsystems GmbH, Wetzlar, Germany). 
Localization of ROS in A2780 cells 
A2780 cells were seeded on confocal 35 mm glass bottom dishes (Mattek, Ashland, USA) at a 
density of 1.5 × 105 cells per dish and cultured overnight. Then, the cells were treated with 1 at 
a concentration of 5 μM or supplemented with fresh culture medium. Cells were incubated for 
90 min under dark conditions followed by 30 min of irradiation with blue light (420 nm; 77 W 
m−2). A set of samples were also incubated under dark conditions after the treatment. Then the 
cells were subsequently stained with ER tracker and CellROX reagent, washed twice with PBS 
and fixed with 4% formaldehyde for 15 min at room temperature. Cells were visualized on a 
confocal microscope Leica TSC SP8 SMD. 
Statistical analysis 
If not otherwise stated, the same symbols were used throughout the study to highlight 
statistically significant differences. Stars (*) at the top of the bars indicate a significant 
difference from the untreated control. Statistical difference between the irradiated and non-
irradiated samples is marked with the hash (#). Statistical significance was calculated using the 
two-way analysis of variance (ANOVA) and unpaired Student’s t-test with p ≤ 0.01. 
Conclusions 
The results of our work might have broad implications for photoactivated chemotherapy of 
cancer owing to the current extensive use of platinum-based drugs in cancer treatment. 
Strategies based on simultaneous induction of ICD and DNA damage by platinum drugs upon 
light irradiation may result in efficient antitumor activity, taking advantage of the selective and 
targeted activation in tumor cells. 
Collectively, our results warrant further investigation into the use of PtIV-based diazido 
compounds in photoactivated chemotherapy for the treatment of human tumors. They also 
highlight the importance of photoactivatable platinum complexes for synergistic enhancement 
of their anticancer efficiency due to their immunomodulating capacity. 
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